Hainan Haiyao: Announcement of Resolutions of the 15th Meeting of the 11th Board of Directors
Hainan Haiyao: Asset Assessment Report for Fixed Assets, Projects Under Construction, and Land Use Rights Asset Value Projects Involving Jiangsu Pujian Pharmaceutical Co., Ltd. plans to transfer assets
Hainan Haiyao: Notice on Abnormal Stock Trading Fluctuations and Risk Alerts
Hainan Haiyao: Announcement on the Disposal of Idle Assets by Jiangsu Pujian Pharmaceutical Co., Ltd.
Hainan Haiyao: Announcement on Abnormal Fluctuations in Stock Trading
Hainan Haiyao: Announcement on the impact of the typhoon
Hainan Haiyao: Summary of the 2024 Semi-Annual Report
Hainan Haiyao: Semi-annual Non-Operating Capital Occupancy and Other Related Capital Transactions Summary
Hainan Haiyao: 2024 Semi-Annual Financial Report
Hainan Haiyao: Semi-Annual Report Board Resolution Announcement
Hainan Haiyao: 2024 Semi-Annual Report
Hainan Haiyao: Financial business risk assessment report on deposits and loans related to Hainan Haiyao Co., Ltd. and Xinxing Jihua Group Finance Co., Ltd.
Hainan Haiyao: Announcement of the resolution of the thirteenth meeting of the eleventh board of directors.
Hainan Haiyao: Announcement on the Mid-term Analysis Results of Phase II Clinical Trial of Fluorfenilone Capsules
Hainan Haiyao: Announcement regarding the resignation of Vice Chairman.
Hainan Haiyao: Announcement of the company's equity license and distribution agreement signed with Greece's PHARMATHEN S.A.
Hainan Haiyao: Announcement regarding the quality and efficacy consistency evaluation of generic cefoperazone sodium for injection.
Hainan Haiyao: 2024 Interim Performance Forecast
Hainan Haiyao: Announcement on the company's exclusive commercialization rights agreement with AFT Pharmaceuticals Ltd for Crystaderm products in New Zealand.
Hainan Haiyao: Announcement Regarding the Progress of Litigation.
No Data
No Data